Annexon (ANNX) vs Gyre Therapeutics (GYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Annexon (ANNX) has outperformed Gyre Therapeutics (GYRE) over the past year, gaining 23.3% versus a loss of 1.5%. Over five years, ANNX leads with a -81.7% price change compared with -88.3% for GYRE. Annexon is the larger company by market cap ($762.1 million vs $746.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANNX | GYRE |
|---|---|---|
| Share price | $4.02 | $7.04 |
| Market cap | $762.11M | $746.48M |
| 1-day change | +0.50% | +4.14% |
| YTD return | -19.92% | -0.28% |
| 1-year return | +23.31% | -1.54% |
| 5-year return | -81.73% | -88.27% |
| Forward P/E | — | 117.33 |
| EPS (TTM) | $-1.14 | $-0.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.18 | $9.42 |
| 52-week low | $2.54 | $5.44 |
| Distance from 52-week high | -44.01% | -25.27% |
| Analyst consensus | buy | none |
| Avg. price target upside | +283.83% | +165.20% |
| Average volume | 3.08M | 105.93K |
| Shares outstanding | 189.58M | 106.03M |
| Employees | 92 | 625 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANNX has outperformed GYRE by 24.9 percentage points over the past year.
About Annexon
ANNX stock →Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Gyre Therapeutics
GYRE stock →Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees
ANNX vs GYRE FAQ
Which is bigger, Annexon or Gyre Therapeutics?
Annexon (ANNX) is larger, with a market capitalization of $762.11M compared with $746.48M for Gyre Therapeutics (GYRE).
Which stock has performed better over the past year, ANNX or GYRE?
ANNX returned +23.31% over the past 12 months, compared with -1.54% for GYRE (price return, excluding dividends). Past performance does not predict future results.
Are Annexon and Gyre Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.